SCIENTURE's Strategic Agreement to Boost Arbli Market Access
SCIENTURE Secures Major Agreement for Arbli™ Accessibility
Arbli™ stands out as the first ready-to-use liquid formulation of losartan, providing a significant leap in patient care by eliminating compounding needs, offering reduced dosing volume, and ensuring a convenient extended room-temperature shelf life.
Expanding Access in the Healthcare Sector
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) has recently formalized a pivotal agreement with a leading Pharmacy Benefit Manager (PBM) to enable broader access for Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL. This agreement is designed to assure formulary coverage for over 100 million lives, highlighting SCIENTURE's commitment to patient affordability and access to essential medicines.
The Significance of the GPO Rebate Agreement
Securing this major pharmacy benefit manager-led Group Purchasing Organization (GPO) rebate agreement is not just a milestone; it's a strategic move to position Arbli™ favorably within the $256 million U.S. losartan market. Discussions for further enhancing both commercial and government coverage for the product are also ongoing.
About Arbli™ and Its Clinical Benefits
Arbli™ has gained FDA approval for use in treating hypertension among patients over six, helping reduce the risk of strokes in patients suffering from hypertension and left ventricular hypertrophy. This groundbreaking product uniquely serves those requiring a liquid formulation, ensuring quality and dosing accuracy that traditional compounded prescriptions may fail to provide.
A Novel Solution for Patients
This novel formulation ensures that patients and caregivers have easier access to their medication. The innovative nature of Arbli™ also comes with the assurance of a long shelf life when stored at room temperature, distinguishing it from existing oral solid forms of losartan on the market.
The U.S. Losartan Market Landscape
According to recent data, the U.S. losartan market generates around $256 million annually, with a prescription volume reaching approximately 71 million. Historically, all available losartan options have been in solid form, which underscores the importance of Arbli™ as a liquid alternative, particularly for those unable or unwilling to take tablets.
Impact on Healthcare Providers and Patients
“This accomplishment aligns with our mission to make Arbli™ highly accessible to those who need it,” stated Narasimhan Mani, President and co-CEO. This agreement is anticipated to reduce reimbursement barriers, facilitating smoother access to treatment.
Executive Chairman Shankar Hariharan also emphasized the benefits this agreement brings: “Our collaboration with these health plans allows us to enhance healthcare delivery while ensuring operational efficiency.”
Understanding Arbli™ in the Market
Arbli™ is the first and only oral liquid formulation of losartan that is FDA-approved in the U.S. With a peppermint flavor, it is packaged in a 165 mL bottle and does not need refrigeration. The shelf life is confirmed for 24 months, showcasing its robustness and reliability.
Safety and Usage Information
Patients are advised against using Arbli™ if pregnant due to potential risks to the developing fetus. Additionally, it should not be used in combination with aliskiren for those with diabetes or renal issues. Common side effects include dizziness and respiratory issues, emphasizing the need for patients to stay informed.
What Is Hypertension?
Hypertension, or high blood pressure, poses a serious health concern affecting nearly half of U.S. adults, leading to conditions such as stroke and heart disease. Understanding hypertension’s prevalence and risk factors is crucial for healthcare discussions and interventions.
About SCIENTURE HOLDINGS, INC.
SCIENTURE HOLDINGS, INC., with its subsidiary Scienture, LLC, dedicates itself to refining patient care through innovative pharmaceutical products. By addressing significant unmet medical needs, the company aims to enhance value for patients and healthcare providers alike.
Frequently Asked Questions
What is Arbli™ used for?
Arbli™ is used for treating hypertension and reducing stroke risk in specific patients. It is also used for diabetic nephropathy in particular patients.
How does Arbli™ differ from traditional losartan?
Arbli™ is a liquid formulation, eliminating the need for compounding, thus ensuring dosing accuracy and ease of use, particularly for those who prefer a liquid alternative.
What safety precautions should be taken with Arbli™?
Patients should avoid taking Arbli™ during pregnancy and should consult healthcare providers if they have kidney or liver issues or are on aliskiren.
How can I access Arbli™?
Arbli™ can be accessed through pharmacies participating in the formulary coverage facilitated by the recently secured PBM agreement.
Where can I find more information about SCIENTURE?
More information about SCIENTURE and its products can be found on their official websites: www.scientureholdings.com and www.scienture.com.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
